Lantus Solostar, an insulin glargine injection with a concentration of 100 units/mL, is available in pharmacies. DrugPatentWatch.com tracks patent and exclusivity information for medications like Lantus Solostar.
How much does Lantus Solostar cost?
The price of Lantus Solostar can vary significantly depending on factors such as pharmacy, location, insurance coverage, and any available discounts or savings programs. It is advisable to check with local pharmacies for the most current pricing information.
When does Lantus Solostar's patent expire?
Information regarding the patent expiry of specific medications like Lantus Solostar is tracked by entities such as DrugPatentWatch.com [1]. Patents protect the exclusive rights of the innovator company to market a drug for a certain period.
Are there lower-cost alternatives to Lantus Solostar?
Following patent expiry, generic versions or biosimilars of a drug may become available, potentially offering lower costs. The availability and pricing of these alternatives depend on regulatory approvals and market dynamics.
What is insulin glargine and how does Lantus Solostar work?
Insulin glargine is a long-acting insulin analog used to treat type 1 and type 2 diabetes. It provides a basal (background) insulin level that helps to control blood glucose levels throughout the day and night. Lantus Solostar is a pre-filled insulin pen designed for convenient self-administration of insulin glargine.
Who manufactures Lantus Solostar?
Lantus Solostar is manufactured by Sanofi [2].
What is the difference between Lantus and Lantus Solostar?
Lantus is the brand name for Sanofi's insulin glargine product, which was historically available in vials and cartridges. Lantus Solostar is a specific pre-filled insulin pen delivery system for insulin glargine, designed for ease of use and precise dosing [2].
What clinical trials have been conducted for insulin glargine?
Numerous clinical trials have been conducted to evaluate the efficacy and safety of insulin glargine in various patient populations with diabetes. These trials inform the approved uses and prescribing information for the medication.
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.sanofi.com/